Skip to main content

Need Immediate Care?

Find Urgent Care Locations

Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)

Short Title: S1931 (PROBE Trial)


Enrollment Status: Recruiting

NCT #: NCT04510597

Specialty Area: Oncology

Condition Studied: Metastatic Renal Cell Carcinoma

Age Groups: Adult; Older Adult

Phase: III


Study Information

Summary / Purpose

This study is for people with kidney cancer (renal cell carcinoma) that has spread to other parts of the body. Everyone in the study receives a standard immunotherapy-based drug combination. The study looks at whether adding surgery to remove the kidney tumor after that treatment works differently than continuing the drug treatment alone.

Surgery to remove the primary kidney tumor when cancer has already spread is called a cytoreductive nephrectomy. Doctors do not yet agree on when, or whether, this surgery helps people who are also receiving modern immunotherapy-based treatment. This trial is designed to help answer that question.

Researchers hope to learn how the two approaches compare in terms of how long people live, how the cancer responds to treatment, side effects, and quality of life. The full technical description of the study is listed in the national clinical trials registry under identifier NCT04510597.

Taking part is voluntary. Your care team will explain the study in detail, answer your questions, and you may choose to stop participating at any time.

Study Type: Interventional
Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

This study is enrolling adults with metastatic kidney cancer whose primary kidney tumor is still in place. The points below are a short summary of the main requirements, not the full eligibility list.

Some of the main requirements

  • Adults 18 years of age or older
  • A confirmed diagnosis of clear cell or non-clear cell renal cell carcinoma (kidney cancer) that has spread to other parts of the body
  • The kidney tumor has not been surgically removed
  • Well enough to safely have kidney surgery, based on your doctor's assessment
  • Blood tests and organ function (such as kidney, liver, and blood counts) within the ranges required by the study
  • Willing and able to receive standard immunotherapy-based drug treatment and attend study visits

Some reasons a person may not be able to join

  • Active cancer that has spread to the brain
  • Having only one kidney, or a transplanted kidney
  • Other medical conditions that would make surgery or study treatment unsafe

The study team reviews your medical history, test results, and imaging to confirm whether this trial is a fit for you. If you are interested, talk with your doctor or contact the study team listed for this trial.

What's Involved

Participation in the study will include:

If you join, you will first receive standard systemic therapy, then be placed by chance (randomly) into one of two groups. Your care team will walk you through each step before it happens.

Steps in the study

  • Receiving standard systemic therapy for about 6 to 18 weeks before random assignment. Depending on the regimen your doctor selects, this may include drugs given through a vein (intravenously, or IV) and a drug taken by mouth.
  • Imaging scans to see how the cancer is responding to the drug treatment.
  • Random assignment (like a coin toss) to one of two groups: continue immunotherapy-based drug treatment alone, or continue that treatment and also have surgery to remove all or part of the kidney (nephrectomy).
  • Continuing immunotherapy-based drug treatment, given by IV and by mouth, after random assignment.

Visits, tests, and follow-up

  • Regular clinic visits for treatment, physical exams, and blood tests
  • Imaging scans at planned points to monitor the cancer
  • Questionnaires about how you are feeling and your quality of life
  • Follow-up visits that continue after treatment ends so the study team can check on your health over time

How long you take part depends on how your cancer responds and how you are doing overall. The study team will explain the expected schedule, the possible risks and side effects, and any costs before you decide. You may leave the study at any time.

Principal Investigator

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

ER Wait Times

How are wait times calculated?

Our estimated ER wait times reflect the average time from check-in to being seen by a medical professional during triage, where patients are prioritized based on the severity of their condition.